Biosynex announces that ProciseDx, its subsidiary specializing in the development of a delocalized biology system, has signed a strategic agreement with Revvity Euroimmun US for the exclusive distribution of its platform in the US and Canadian markets.

The ProciseDx platform was the first to receive de novo FDA approval in September 2023 for assays for Remicade, Humira and their biosimilars used in therapeutic drug monitoring.

PociseDx will leverage Euroimmun US's expertise in the distribution of in vitro diagnostic systems to target key market segments. In addition, it will retain direct access to some thirty prospects with whom it has initiated referral discussions.

Copyright (c) 2024 CercleFinance.com. All rights reserved.